Evidence map›Paper›PMID 38534698›Full record

ArticleAntibiotics (Basel, Switzerland)2024

Biofilm Development by

Arij Akir, Abrar Senhaji-Kacha, Maria Carmen Muñoz-Egea, Jaime Esteban, John Jairo Aguilera-Correa

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.International journal of molecular sciences · 2024
    Review
  3. Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Arij AkirDepartment of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.
Abrar Senhaji-KachaDepartment of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0003-0031-0976
Maria Carmen Muñoz-EgeaDepartment of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0003-2457-7165
Jaime EstebanDepartment of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-8971-3167
John Jairo Aguilera-CorreaDepartment of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-4002-1944
Centro de Investigación Biomédica en Red · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe

methodsThree collection strains (

resultsThe strains showed differences between them with all the studied parameters, but neither a species-specific pattern nor a clinical-significance-specific pattern were detected. For the effect of clarithromycin, the viability of the bacteria contained in the biofilm was inversely proportional to the exposure time of the biofilm (ρ > -0.3;

conclusionsAll the

Indexed as

BiofilmclarithromycinmacrolidesMycobacterium aviumMycobacterium avium complexMycobacterium chimaeraMycobacterium intracellulare

Identifiers

PMID38534698
PMCPMC10967565
OpenAlexW4392918976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.